antibacterial compounds intended to address high-need medical conditions that can be life-threatening without effective treatment. Its portfolio includes medicines developed to inhibit viruses such as cytomegalovirus and herpes simplex virus, along with additional programs targeting other viral infections and multidrug-resistant bacteria. AiCuris also collaborates with research partners and participation programs to explore new targets and active agents for infection prevention and therapy. The organization conducts clinical trials to evaluate the safety and efficacy of its product candidates and supports initiatives that extend its scientific expertise in anti-infective drug development. Through licensing arrangements with healthcare partners, some of its developed therapies are brought into broader clinical use while it continues to advance its pipeline of investigational treatments.